Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,685
Stocks News & Analysis
stocks
Wildly overvalued ASX stock is skating on thin ice
stocks
Uber flexes its network effect and delivers strong result
stocks
Ask the analyst: Are Qantas shares a value trap?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,102.00 | 9.10 | -0.10% |
CAC 40 | 7,732.87 | 97.84 | 1.28% |
DAX 40 | 24,325.78 | 401.42 | 1.68% |
Dow JONES (US) | 44,409.19 | 216.07 | 0.49% |
FTSE 100 | 9,110.92 | 53.39 | -0.58% |
HKSE | 25,081.63 | 171.00 | 0.69% |
NASDAQ | 21,357.71 | 188.29 | 0.89% |
Nikkei 225 | 41,059.15 | 264.29 | 0.65% |
NZX 50 Index | 12,887.10 | 6.94 | 0.05% |
S&P 500 | 6,381.05 | 35.99 | 0.57% |
S&P/ASX 200 | 8,831.40 | 12.30 | -0.14% |
SSE Composite Index | 3,639.67 | 5.67 | 0.16% |